The Impact of Glucocorticoid Replacement on Bone Mineral Density in Patients With Hypopituitarism Before and After 2 Years of Growth Hormone Replacement Therapy
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with hypopituitarism have reduced bone mineral density (BMD) and increased fracture risk. OBJECTIVE: The aim of this study was to analyze the effects of glucocorticoid (GC) replacement on BMD before and after 2 years of GH therapy in hypopituitary patients. The main hypothesis was that patients on GC replacement demonstrate greater improvement in BMD when treated with GH. DESIGN: This was a post hoc analysis of data from a prospective single-center study. PATIENTS: Data on 175 adult patients with hypopituitarism and verified GH deficiency due to nonfunctioning pituitary adenoma were analyzed. Ninety-eight (56%) were GC insufficient, receiving a mean ± SD hydrocortisone equivalent dose of 20.9 ± 5.0 mg/d. MAIN OUTCOME MEASURE: BMD before and after 2 years of GH replacement therapy was measured by using dual-energy X-ray absorptiometry. RESULTS: BMD at baseline did not differ between GC-sufficient and -insufficient patients, neither at lumbar spine nor femur neck. After 2 years on GH replacement, BMD increased in both groups. After adjustment for weight, age, gender, free T4 concentrations, change in IGF-I levels, and sex hormone treatment, GC sufficiency was associated with a greater increase in BMD at the femur neck (ΔT-score in GC insufficient patients 0.09 ± 0.46, in GC sufficient patients 0.19 ± 0.43; P < .05) but not at the lumbar spine. CONCLUSIONS: GH replacement therapy for 2 years increased BMD in hypopituitary patients. In contrast to our hypothesis, GC-insufficient patients receiving near physiological doses of hydrocortisone do not show a greater therapeutic response to GH therapy than their GC-sufficient counterparts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another small open crossover study in hypopituitary men randomized to three commonly used HC dose regimens reported that low-dose HC replacement (10 mg a.m. and 5 mg p.m.) was associated with increased bone formation and positive bone remodeling balance and with probable long-term beneficial effects on bone health.( 203)”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [203]
Citations
Cites
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,114
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Giustina, A., Mazziotti, G., & Canalis, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0036 · Cited by 914 · cited 1×
“GH deficiency in adults has been associated with reduced BMD and increased fracture risk (12).”
BackgroundOhlsson, C., Bengtsson, B.-A., Isaksson, O. G. P., Andreassen, T. T., & Slootweg, M. C. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0324 · Cited by 855
Glucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 694
Brabant, G., von zur Mühlen, A., Wüster, C., Ranke, M. B., Kratzsch, J., Kiess, W., Ketelslegers, J.-M., Wilhelmsen, L., Hulthén, L., Saller, B., et al. (2003) · Hormone Research in Paediatrics · doi:10.1159/000071871 · Cited by 360 · cited 3×
“(Nichols Advantage; Nichols Institute Diagnostics) (23).”
Ohlsson, C. (1998) · Endocrine Reviews · doi:10.1210/er.19.1.55 · Cited by 346
Reduced bone mineral density in patients with adult onset growth hormone deficiency
Holmes, S. J. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.3.669 · Cited by 340 · cited 1×
“01 Surgery 139 (79) 69 (90) 70 (71) Radiotherapy 2 (1) 2 (2) Surgery and radiotherapy 27 (15) 8 (10) 19 (19) No treatment 7 (4) 7 (7) Free T4, pmol/L 15.”
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 1×
“Adverse metabolic profile (26), lower BMD (8, 27), and impaired health-related quality of life (28, 29) have all been associated with high GC replacement doses.”
BackgroundSelf-citationHahner, S., Loeffler, M., Fassnacht, M., Weismann, D., Koschker, A.-C., Quinkler, M., Decker, O., Arlt, W., & Allolio, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0685 · Cited by 282 · cited 1×
“Adverse metabolic profile (26), lower BMD (8, 27), and impaired health-related quality of life (28, 29) have all been associated with high GC replacement doses.”
Background
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Mo, D., Fleseriu, M., Qi, R., Jia, N., Child, C. J., Bouillon, R., & Hardin, D. S. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00098-4 · Cited by 64
Xie, F., Lv, D., & Chen, L. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmu032 · Cited by 34
“Several human diseases are caused by some deficiencies of hormonal peptides, and hormonal replacement therapy has been an effective treatment method in clinic [32,33].”
MethodDas, L., Laway, B. A., Sahoo, J., Dhiman, V., Singh, P., Rao, S. D., Korbonits, M., Bhadada, S. K., & Dutta, P. R. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07062-z · Cited by 7
“Though hypocortisolism may not adversely affect bone (or skeleton), glucocorticoid replacement therapy may predispose to osteoporosis in individuals with hypopituitarism [9, 10].”
Metadata
- Authors
- Ragnar Agnarsson, H., Johannsson, G., & Ragnarsson, O.
- Affiliations
- Faculty of Medicine (H.R.A.), University of Iceland, 101 Reykjavik Iceland
- University of Gothenburg (SE)
- Institute of Medicine (G.J., O.R.), Sahlgrenska Academy, University of Gothenburg, SE-413 45 Göteborg Sweden
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 99
- Issue
- 4
- Pages
- 1479-1485
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2042131849
- Semantic Scholar
- 6e9e9b6e4b7c8771037df3366943e91d09a276fa
- Cited by
- 10
- References
- 35
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 1 · 2020: 1 · 2018: 2 · 2016: 1 · 2015: 1 · 2014: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- hypopituitarism, growth hormone replacement therapy, glucocorticoid replacement therapy, bone mineral density, cortisol, glucocorticoid insufficiency, non-functioning pituitary adenoma, fracture risk, femoral neck, lumbar spine, insulin-like growth factor I
- MeSH terms
- Adenoma, Adult, Aged, Female, Glucocorticoids, Humans, Hypopituitarism, Longitudinal Studies, Male, Middle Aged, Pituitary Neoplasms, Retrospective Studies, Bone Density, Human Growth Hormone, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Impact of Glucocorticoid Replacement on Bone Mineral Density in Patients With Hypopituitarism Before and After 2 Years of Growth Hormone Replacement Therapy. https://app.cochat.ai/papers/10.1210/jc.2013-3851
- The paper
- Ragnar Agnarsson, H., Johannsson, G., & Ragnarsson, O. (2014). The Impact of Glucocorticoid Replacement on Bone Mineral Density in Patients With Hypopituitarism Before and After 2 Years of Growth Hormone Replacement Therapy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2013-3851
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.